Osimertinib

SUSPENDED · PHASE2 · Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

Budget Issue

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.